OTCMKTS:NWBO

Northwest Biotherapeutics Stock Forecast, Price & News

$1.29
+0.02 (+1.57 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.23
$1.31
50-Day Range
$1.10
$1.40
52-Week Range
$0.65
$2.51
Volume1.20 million shs
Average Volume1.83 million shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.78
30 days | 90 days | 365 days | Advanced Chart
Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Northwest Biotherapeutics logo

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

What stocks does MarketBeat like better than Northwest Biotherapeutics?

Wall Street analysts have given Northwest Biotherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Northwest Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release its next quarterly earnings announcement on Friday, January 21st 2022.
View our earnings forecast for Northwest Biotherapeutics
.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $0.20 million.
View Northwest Biotherapeutics' earnings history
.

How has Northwest Biotherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Northwest Biotherapeutics' stock was trading at $0.1799 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NWBO shares have increased by 617.1% and is now trading at $1.29.
View which stocks have been most impacted by COVID-19
.

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the following people:
  • Linda F. Powers, Chairman, President & Chief Executive Officer
  • Alton L. Boynton, Secretary, Director & Chief Scientific Officer
  • Marnix L. Bosch, Chief Technical Officer
  • Jean M. Davis, Chief Information Officer
  • Leslie J. Goldman, Senior Vice President & General Counsel

Who are some of Northwest Biotherapeutics' key competitors?

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), TransEnterix (TRXC), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP).

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $1.29.

How much money does Northwest Biotherapeutics make?

Northwest Biotherapeutics has a market capitalization of $1.13 billion and generates $1.29 million in revenue each year.

How many employees does Northwest Biotherapeutics have?

Northwest Biotherapeutics employs 19 workers across the globe.

What is Northwest Biotherapeutics' official website?

The official website for Northwest Biotherapeutics is www.nwbio.com.

Where are Northwest Biotherapeutics' headquarters?

Northwest Biotherapeutics is headquartered at 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at (240) 497-9024 or via email at [email protected]


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.